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ABSTRACT

Individual day-to-day management and effective control of type 1 diabetes (T1D) is
ultimately driven by decisions made by the individual. Individuals with attention deficit
hyperactivity disorder (ADHD) have a higher tendency to be inattentive, impulsive, and
hyperactive. Attention deficits and impulsivity among adolescents and adults with T1D could
result in poor diabetes management through infrequent self-monitoring of blood glucose and
inadequate insulin dosing – key components of achieving optimal glycemic control.
This study included 7,380 adolescents and young adults, ages 13-25 years, participating
in the T1D Exchange clinic registry (median age 17.4 years, duration 7.7 yrs, 50% female, 81%
white). Participants were classified into 3 groups for the primary analyses using participant
reported diagnosis and medication use: 1) No ADHD; 2) ADHD with current medication; 3)
ADHD without current medication. Groups were compared in logistic and linear regression
models for: self-monitoring of blood glucose (SMBG) /day, missed insulin dose ≥1 time/week,
HbA1c, and at least 1 diabetic ketoacidosis (DKA) and severe hypoglycemic (SH) event in the
past 3 months.
Overall, 774 (10%) participants reported a diagnosis of ADHD of whom 371 currently
took medication. Mean SMBG/day was 4.7, 5.0, and 4.9 in the ADHD w/o meds, ADHD with
meds, and no ADHD groups, respectively. ADHD patients w/o meds (36%, P=0.02) or with
meds (39%, P=0.003) were more likely to report missing insulin doses compared with no ADHD
pts (30%). Mean HbA1c was higher in ADHD w/o meds (9.0%, P<0.001) and ADHD with
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meds (8.9%, P=0.002) compared with no ADHD pts (8.6%). The odds of having at least one
DKA event in the past 3 months was 1.8 and 1.5 times higher in the ADHD w/o meds (P<0.001)
and ADHD with meds (P=0.01) group compared with no ADHD. The ADHD w/o meds group
was significantly more likely to have had a SH event (OR 1.7 95% CI 1.2-2.3; P<0.001)
compared with the no ADHD group but the occurrence of SH in the ADHD with meds group
was similar to the no ADHD.
Results of this study supported the working hypothesis that ADHD without treatment
with medication has a negative impact on aspects of diabetes management and glycemic control.
Participants with ADHD with and without medication were more likely to miss insulin doses,
less likely to use an insulin pump, more likely to have high HbA1c levels, and had a higher
frequency of DKA and SH. These results have important public health implications for
adolescents and young adults with T1D who are already at risk for poor glycemic control. Since
ADHD has a meaningful impact on glycemic outcomes it is important for providers of
adolescents and young adults with T1D to review history and signs of an ADHD diagnosis along
with diagnosis of other psychosocial disorders with their patients and consider recommending
psychosocial services.
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CHAPTER 1:
INTRODUCION

Individual day-to-day management and effective control of type 1 diabetes (T1D) is
ultimately driven by decisions made by the individual. Individuals with attention deficit
hyperactivity disorder (ADHD) have a higher tendency to be inattentive, impulsive, and
hyperactive. Attention deficits and impulsivity among adolescents and adults with T1D could
result in poor diabetes management through infrequent self-monitoring of blood glucose and
inadequate insulin dosing – key components of achieving optimal glycemic control. The role of
ADHD on glycemic control among adolescents and adults with T1D has not been studied. Lack
of such knowledge is an important public health problem because poor glycemic control is
causally related to long- term microvascular complications of T1D, such as retinopathy and
nephropathy as well as macrovascular complications such as coronary artery disease.
The specific aims for this proposal are as follows:

1. Compare Glycemic Control among Adolescents and Young Adults with T1D across ADHD
Status Groups.
Working hypothesis: Adolescents and adults with T1D and untreated ADHD will have
worse glycemic control compared with those without ADHD.
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2. Assess the Relationship between ADHD Status and Diabetes Management Including
Frequency of Self-Monitoring of Blood Glucose and Insulin Administration in Adolescents
and Young Adults with T1D.
Working hypothesis: Adolescents and adults with T1D and untreated ADHD will check
their blood sugar less often and be more likely to miss an insulin dose.

3. Assess the Association between ADHD Status and the Frequency of Diabetic Ketoacidosis
(DKA) and Severe Hypoglycemia among Adolescents and Young Adults with T1D.
Working hypothesis: Adolescents and adults with T1D and untreated ADHD will have a
higher frequency of DKA and severe hypoglycemia compared with those without ADHD.

The expected outcome of these aims will identify whether or not ADHD adversely
influences the day-to-day management of T1D among adolescents and young adults 13 -<26
years of age. Such results are expected to have an important health impact because they will lead
to the determination of optimal treatment regimens and behavioral interventions for this special
population.
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CHAPTER 2:
LITERATURE REVIEW

Type 1 Diabetes
Type 1 diabetes (T1D) is an autoimmune disorder, characterized by immune system
destruction of the insulin producing beta cells of the pancreas. The exact trigger of the
destruction of the beta cells is not known but it is believed that both genetic and environmental
factors play a role. The well-known model for the natural history of T1D is a process where
individuals who are at a genetic risk for T1D with a set number of beta cells are exposed to some
type of environmental trigger that sets off an autoimmune reaction where islet related antibodies
develop and t-cells begin destroying beta cells resulting in the near complete loss of endogenous
insulin (Atkinson & Chervonsky, 2012; Eisenbarth, 1986). The marked or complete loss of
endogenous insulin, in the absence of exogenous insulin administration will lead to death.

Diagnosis of T1D
According to American Diabetes Association (ADA) clinical guidelines, a diagnosis of
diabetes should be made if any of the following are present (1) Hemoglobin A1c of ≥ 6.5%, (2)
fasting plasma glucose ≥126 mg/dL (7.0 mmol/L), (3) 2 hour plasma glucose ≥ 200mg/dL
(11.1mmol/L) during an oral glucose tolerance test (OGTT), or (4) random plasma glucose of ≥
200mg/dL with common symptoms of hyperglycemic crisis including polyuria, polydipsia, and
unexplained weight loss (American Diabetes Association, 2015). Generally people with type 1
diabetes present with acute symptoms and it is not uncommon for diabetic ketoacidoses (DKA),
3

a life threatening condition, to occur at onset. In approximately 85-90% of T1D cases, evidence
of the autoimmune beta cell destruction process is evident through the presence of antibodies
including islet cell, GAD, IA-2, IA- 2β, or insulin autoantibodies (Donaghue, Chiarelli, Trotta,
Allgrove, & Dahl-Jorgensen, 2007).
T1D is most often diagnosed in children and adolescents and at one time was referred to
as juvenile diabetes. The presentation of T1D most commonly occurs between 5-7 years of age
and around puberty (Harjutsalo, Sjoberg, & Tuomilehto, 2008). Recently, more cases of T1D
are being diagnosed in adulthood. Diagnosing T1D in adulthood is particularly challenging due
to the growing rates of adult obesity which muddles the distinction between type 1 and type 2
diabetes. A different classification of T1D referred to as latent autoimmune diabetes in
adulthood or LADA has grown popularity over the past decade (Pozzilli & Di Mario, 2001;
Zimmet, Turner, McCarty, Rowley, & Mackay, 1999). Whether or not T1D that presents in
adulthood is the same disease that presents in childhood is not clear. Individuals diagnosed as
adults tend to have more C-peptide at diagnosis, an assessment of endogenous insulin
production, and are able to preserve C-peptide for longer durations (Merger, Leslie, & Boehm,
2013) Adults with LADA can often regulate glucose with oral medications without the need for
insulin for some period of time but eventually require exogenous insulin (Merger et al., 2013). It
is estimated that 20% of all adults diagnosed with type 2 diabetes actually have LADA (LandinOlsson, 2002). Most T1D cases show evidence of autoimmunity such as presence of diabetes
related antibodies or genes controlling the immune response, however this is not true for all
cases. Cases of T1D that have evidence of an immune related pathogenesis are referred to as
type 1A or autoimmune diabetes. Around 80% of T1D cases are classified as type 1A and the
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remaining cases are referred to as type 1B or idiopathic T1D without a known autoimmune cause
(Atkinson, Eisenbarth, & Michels, 2014; Eisenbarth, 2007).

Epidemiology of T1D
The Search for Diabetes in Youth (SEARCH) study was designed to assess incident and
prevalent cases of diabetes in youth < 20 years of age in the US. In SEARCH, incidence rates of
T1D per 100,000 person years were 14.3 (12.9-15.9) in 0-<5 year olds, 22.1 (20.3-24.1) in 5-<
10 year olds, 25.9 (24.0-27.9) in 10<15 year olds, and 13.1 (11.8-14.6) in 15-<20 year olds
(Dabelea et al., 2007). The Diabetes Mondiale (DiaMond) project group assessed the incidence
of type 1 diabetes in children < 14 years of age from 1990-1994 in 50 difference countries.
There was a wide variation between countries with incidence of T1D ranging from 0.1/100,000
per year in China and Venezuela to 36.8/100,000 per year in Sardinia and 36.5/100,000 per year
in Finland ("Incidence and trends of childhood Type 1 diabetes worldwide 1990-1999," 2006).
Similar results were observed in the EURODIAB ACE study group which assessed the incidence
of T1D in 44 centers across Europe and Israel among approximately 28 million children.
Incidence rates in the EURODIAB study ranged from 3.2 in Macedonia to >40 per 100,000
person years in Finland (Patterson, Dahlquist, Gyurus, Green, & Soltesz, 2009). Incidence of
T1D in adults is less common than in children, however approximately 25% of individuals with
T1D are diagnosed as adults. Incident cases have been rising over the past decade with
increases of 2.4% in Finland, 2.6% in Germany, and 3.3% in Norway with the most substantial
incidence rise occurring in children < 5 years of age (Atkinson et al., 2014). The exact reason
for the rise in incident cases is not known but has been credited to environmental risk factors
(Atkinson et al., 2014).
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There are both genetic and environmental risk factors for T1D. In the general population
the lifetime risk of developing T1D is about 0.4% (Mehers & Gillespie, 2008). The risk for
someone with a first degree relative affected by T1D ranges from 1% to 6% depending on the
affected relative, with the highest risk if a sibling or father has T1D (3% to 6%) and lowest if a
Mother has T1D (1% to 2%) (Steck et al., 2005). The rate of T1D concordance has been shown
to be approximately 23% in monozygotic twins and approximately 4% in dizygotic twins
(Hyttinen, Kaprio, Kinnunen, Koskenvuo, & Tuomilehto, 2003). An association with the human
leukocyte antigen (HLA) was discovered in the early 1970s (Cudworth & Woodrow, 1975;
Singal & Blajchman, 1973). HLA variants account for approximately 50% of the genetic risk for
T1D (Lambert et al., 2004). The risk of type 1 diabetes has been shown to be strongest among
certain combination of HLA-DR-DQ genotypes particularly the DRB1, DQA1 and DQB1 alleles
(Erlich et al., 2008). Other genetic contributors include polymorphisms in encoding proinsulin
and PTPN22 that influence T-cell regulation (Bell, Horita, & Karam, 1984; Bottini et al., 2004).
Studies of environmental risk factors have shown an increase in incident cases among
children born in the Spring and cases are most likely to present in the Autumn and Winter
months ("The Environmental Determinants of Diabetes in the Young (TEDDY) Study," 2008,
Kahn et al., 2009; Moltchanova, Schreier, Lammi, & Karvonen, 2009). T1D has been shown to
occur more frequently among Caucasians, those with higher income and education, and males
(Dabelea et al., 2007; Ostman et al., 2008). Other risk factors that have been shown to be
associated with T1D include vitamin D deficiency in childhood (Blanton et al., 2011; Maclaren
& Atkinson, 1992; Mohr, Garland, Gorham, & Garland, 2008; Svoren, Volkening, Wood, &
Laffel, 2009), early infant formula feeding (Gerstein, 1994; Knip, Virtanen, & Akerblom, 2010),
and viruses in childhood (Bach & Chatenoud, 2012; Boerner & Sarvetnick, 2011; Stene &
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Rewers, 2012; Yeung, Rawlinson, & Craig, 2011). The EURODIAB study found a reduction in
incidence of diabetes among children who received vitamin D supplementation.A large Finnish
cohort study suggested a dose response effect with lower incidence of T1D in children who were
receiving the highest amount of vitamin D supplementation. In this study there was an 80%
reduction in the incidence of T1D among the group of children receiving vitamin D
supplementation. Among those taking supplements, a further reduction in risk of 86% was
observed for those taking at least 2000 mg. Early formula feeding or exposure to cow’s milk has
been shown to be associated with an increase in the risk of T1D (Virtanen et al., 1993).
However, the Diabetes Autoimmunity Study in the Young found no association between early
cow’s milk exposure and beta cell autoimmunity among children with a high genetic risk for
diabetes (Norris et al., 1996). Several large cohort studies have found an association between
maternal enterovirus infection during pregnancy or at the time of delivery, and T1D onset in
childhood. Other studies report an association between enterovirus exposures in childhood
preceding diabetes onset. The large EURODIAB cohort study found associations with maternal
preeclampsia, old maternal age, respiratory disease in infancy, and blood group incompatibility
between infant and mother (Dahlquist, Patterson, & Soltesz, 1999). Two more recent
pathogenesis hypotheses implicate hygiene and gut microbiome alterations(Boerner &
Sarvetnick, 2011).
The rate of insulin production loss in T1D varies between individuals, with the decline of
beta-cell function occurring more rapidly in children than adults (ADA 2013 diagnosis and
classification of Diabetes). Following diagnosis, there is a often a period referred to as the
“honeymoon period” where some residual beta cell function is present resulting in a reduced
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need for exogenous insulin. As residual beta cell function declines, the complexity of diabetes
management of T1D increases and optimal glycemic control becomes more difficult to achieve.

History of T1D Management
Up until 1923 when insulin was first discovered, T1D was a fatal disease marked by
frequent urination with a sweet smell and extreme weight loss due to insulin deficiency
(Polonsky, 2012). Frederick Banting and Charles Best were the first to extract insulin from
healthy dogs’ pancreases and insert it into a dog without a pancreas resulting in the lowering of
the dog’s glucose levels. Banting, Best, and colleagues purified insulin from bovine pancreases
and treated the first human with an insulin injection in 1923 (Bliss, 1993). Once insulin
injections became available, the life expectancy of someone with diabetes increased from only a
few short weeks or months to decades. Subsequent innovations in insulin therapy have
dramatically improved the lives of individuals living with T1D. In the 1950s, NovoNordisk
began producing an intermediate acting hypurin isophane insulin known as NPH (American
Diabetes Association, 2014). NPH is longer acting than regular insulin. In 1963 insulin became
the first human protein to be chemically synthesized and in 1978 was the first human protein to
be synthetically manufactured by using bacteria to grow the protein. Synthetic insulin,
synthesized using the human insulin gene, was called ‘human insulin’ to distinguish it from the
animal derived insulin (Chance & Frank, 1993). The use of synthetic insulin eliminated allergic
reactions at the injection site and became widely available in the 1980s (Polonsky, 2012). In
1976 the first insulin pump was manufactured. The insulin pump delivers insulin continuously
through a process known as subcutaneous insulin infusion (SCII). In 1979, the first clinical trial
comparing SCII with injection therapy was published in the New England Journal of Medicine
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(Tamborlane, Sherwin, Genel, & Felig, 1979). This study showed a significant reduction in
mean plasma glucose among patients using SCII. In 1996 the Food and Drug Administration
approved a modified human insulin analogue called insulin lispro that was specially developed to
be more rapidly active following injection through modification of the amino acid structure of
human insulin. Fast-acting analogue insulin has been shown to improve post-meal glucose
control (Holleman & Hoekstra, 1997). Long acting analogue insulins also were developed to
mimic the body’s production of insulin in the fasted state. Long-acting or basal insulin has a
delayed onset and slow absorption that lasts up to 24 hours.
In the early 19th century, glucose was identified as the sugar substance in urine of people
with diabetes. Prior to the invention of blood glucose meters, self-monitoring of glucose was
performed using urine test strips. Measuring glucose in the urine was problematic since glucose
present in the urine is retrospective by nature and does not represent current blood glucose status
(Clarke & Foster, 2012).

In 1965, glucose began to be tested using blood in the doctor’s office

but not at home. It wasn’t until the 1980s that the first home blood glucose meters for selfmonitoring of blood glucose became available (Clarke & Foster, 2012). Home blood glucose
meters have evolved over the past few decades and are now extremely accurate with the use of
electrode biosensor strips that require a very small amount of blood. Meters now have the
capability to store glucose results and to be downloaded to a computer, facilitating the review of
glucose levels.
In 1999 the FDA approved the first continuous glucose monitor for retrospective use.
Continuous glucose monitoring (CGM) involves the ability to monitor glucose levels in real time
and view trends in and direction of change with alarms for if the glucose is too low or too high.
A CGM utilizes a sensor that is inserted into the skin and a transmitter that communicates with a
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receiver that shows glucose values. The sensor measures the amount of glucose in the interstitial
fluid and is not as accurate as measuring glucose in the blood with a blood glucose meter. The
accuracy and comfort/portability of CGM devices have improved drastically over the past decade
but improvements in accuracy particularly at low blood and high blood glucose levels are still
needed. Real-time CGM devices must be calibrated using a blood glucose meter. CGM is only
FDA approved as an adjunctive device and blood glucose monitoring remains the standard of
care.
Currently, insulin is administered either through injections or through SCII via an insulin
pump. The current standard of care for injection users, is to perform multiple daily injections
(MDI), also referred to as a basal/bolus approach, wherein a long-acting insulin is given once or
twice daily (basal insulin) and a rapid acting insulin is given with meals and to correct elevated
blood sugars. When insulin is given through an insulin pump, insulin is infused continuously at
a basal rate and then boluses of insulin are given with meals or when blood sugar is above target.
The 2015 ADA standards of care for self-monitoring of blood glucose state “Patients on
multiple-dose insulin (MDI) or insulin pump therapy should do SMBG prior to meals and
snacks, occasionally after food, at bedtime, prior to exercise, when they suspect low blood
glucose, after treating low blood glucose until they are normoglycemic, and prior to critical tasks
such as driving” (American Diabetes Association, 2015).

Glycemic Control
Individuals with T1D must take insulin in order to regulate blood glucose levels. Striving
to maintain glucose levels in a normal range, defined as glycemic control, requires constant
balance between insulin, diet, and exercise.
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Glycemic control is often measured using the percentage of glycated hemoglobin
(amount of glucose attached to a red blood cell protein) referred to as hemoglobin A1C or
HbA1c. The A1c corresponds to the amount of sugar in the blood. Since red blood cells have a
turn-over of about 8-12 weeks, the HbA1c can be used to assess the average blood glucose over
the past 2-3 months (Nathan, Singer, Hurxthal, & Goodson, 1984). Over the past few decades,
the HbA1c has become a critical means to assess diabetes care (Gillery, 2013). The ADA and
International Society for Pediatric and Adolescent Diabetes (ISPAD) have established clinical
guidelines for managing diabetes which include glycemic targets based on HbA1c. The ADA
and ISPAD HbA1c target for children and adolescents is < 7.5% and the ADA target for adults is
< 7.0%. (Donaghue et al., 2007) and the ADA HbA1c target for age >19 is < 7.0% (American
Diabetes Association, 2015).
There are both acute and chronic complications of T1D resulting from poor glycemic
control. DKA is a life threatening acute complication characterized by very high blood glucose
and ketones present in the urine or blood. Severe hypoglycemia occurs when the blood sugar
drops dangerously low and can result in seizure, loss of consciousness or coma, and even death.
Chronic complications of T1D include microvascular complications of retinopathy, neuropathy,
and nephropathy as well as macrovascular complications including coronary artery disease and
stroke.
The advent of blood glucose monitoring at home using a meter, insulin analogs, and
insulin pumps greatly improved the ability to achieve optimal glycemic control. The Diabetes
Control and Complications Trial (DCCT), a landmark study in T1D, compared intensive
management of T1D, using multiple daily insulin injections or an insulin pump and frequent selfmonitoring of blood glucose (SMBG), with a conventional therapy control group using 1 or 2
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injections per day. The study showed a marked reduction in HbA1c but at the expense of a
higher frequency of severe hypoglycemia (The Diabetes Control and Complications Trial
Research Group, 1993). Long term follow up of the DCCT cohort has shown that the intensive
therapy group has had a lower risk of retinopathy, nephropathy, and neuropathy as well as
cardiovascular disease (The Diabetes Control and Complications Trial/Epidemiology of Diabetes
Interventions and Complications (DCCT/EDIC) Study Research Group, 2005).
Numerous studies have shown a strong correlation between the frequency of SMBG and
glycemic control (Deiss, Hartmann, Hoeffe, & Kordonouri, 2004; Haller, Stalvey, & Silverstein,
2004; Miller, Beck et al., 2013; Pickup, Freeman, & Sutton, 2011). Recent data from the T1D
Exchange clinic registry of approximately 26,000 individuals with T1D demonstrated a mean
HbA1c of 8.6% in participants who reported testing 3-4 times per day compared with 7.6% in
participants testing ≥ 10 times per day (Miller, Beck et al., 2013). In addition to SMBG
frequency, other diabetes management factors that have been associated with good glycemic
control in the T1D Exchange clinic registry include: use of an insulin pump, missing fewer
insulin doses, giving an insulin bolus (short-acting insulin given at meal time) prior to a meal vs.
during or after a meal, altering insulin to carb ratios according to meals, giving insulin with
daytime snacks, using a higher ratio of short-acting insulin or bolus insulin to long-acting or
basal insulin, and using a lower total daily insulin dose (Campbell, 2013; Simmons, 2013).
A 2008 study conducted by the Juvenile Diabetes Research Foundation Continuous
Glucose Monitoring Group found a significant difference in HbA1c among adults age 25 or older
randomized to use CGM compared with a control group (The Juvenile Diabetes Research
Foundation Continuous Glucose Monitoring Study Group, 2008). A significant treatment group
difference in HbA1c was not observed in the 8-<15 or 15-<25 age groups.
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Poor glycemic control has been associated with depression and anxiety disorders
(Collins, Corcoran, & Perry, 2009; Hood et al., 2006), although which is the cause and which the
effect is unclear. Incidences of DKA and severe hypoglycemia also have been associated with a
diagnosis of a psychiatric disorder in children and adolescents with T1D (Rewers et al., 2002).
Although depression and anxiety have been shown to be strongly correlated with ADHD,

the

relationship of ADHD with glycemic control among individuals with T1D has not been well
studied.

ADHD
Attention deficit/hyperactivity disorder is the most common neurobehavioral disorder of
childhood-onset and is characterized by inattentiveness, impulsive behavior, and hyperactivity
(Biederman & Faraone, 2005; Rowland, Lesesne, & Abramowitz, 2002). The Diagnostic and
Statistical Manual of Mental Disorders, fourth edition (DSM-IV) classifies ADHD into 3 types:
predominately inattentive type (ADHD-I), predominately hyperactive type (ADHD-H), and a
combined type (ADHD-C) (A. P. Association, 2000). ADHD primarily affects executive
functioning causing impairment in attention, working memory, inhibitory processes, set-shifting,
and fluency (Barkley, 1997; Kenemans et al., 2005). However, aspects of impaired social
cognition and incentive/reward processes appear to play a role (Castellanos, Sonuga-Barke,
Milham, & Tannock, 2006; Uekermann et al., 2010). The theoretical model proposed by
Barkley suggests a primary deficit in inhibitory processes that impacts all other aspects of
executive functioning and results in impaired social intelligence (Barkley, 2000). Compared
with age-matched controls, children with ADHD have been shown to have smaller brain volume
of the total cortex, cortical grey matter, frontal cortex, caudate nucleus, cerebellum, and anterior
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cingulated cortex (Bledsoe, Semrud-Clikeman, & Pliszka, 2011). ADHD is a heterogeneous
disorder and a single deficit in brain functioning cannot be pinpointed.

ADHD Diagnosis
The DSM-IV has specific criteria for diagnosing ADHD. Symptoms must appear before the age
of 7 and persist for at least 6 months. Table 1 below describes the criteria for a diagnosis of
ADHD from the DSM-IV (A. P. Association, 2000). The diagnosis of ADHD is often made by a
primary care physician rather than a psychologist or psychiatrist (Rowland, 2002). A 1999 study
by Wasserman et al reported only 38% of primary care physicians use the DSM criteria to
diagnose ADHD (Wasserman et al., 1999). There are no laboratory tests available to diagnose
ADHD. The best method to accurately diagnose ADHD utilizes parent and teacher rating scales
and/or interviews that can be highly subjective (Rowland et al., 2002).

Table 1. DSM-IV Criteria for Diagnosis of ADHD
All criteria below must be met for diagnosis of ADHD based on DSM-IV
1. Either (A) or (B) must be met:
(A) six or more of the following symptoms of inattention have persisted for at least 6 months
to a degree that is maladaptive and inconsistent with developmental level:
Inattention:
1) often fails to give close attention to details or makes careless mistakes in schoolwork,
work, or other activities
2) often has difficulty sustaining attention in tasks or play activities

14

Table 1. (Continued)
3) often does not seem to listen when spoken to directly
4) often does not follow through on instructions and fails to finish schoolwork, chores, or
duties in the workplace (not due to oppositional behavior or failure to understand
instructions)
5) often has difficulty organizing tasks and activities
6) often avoids, dislikes, or is reluctant to engage in tasks that require sustained mental
effort (such as schoolwork or homework)
7) often loses things necessary for tasks and activities (e.g., toys, school assignments,
pencils, books, or tools)
8) is often easily distracted by extraneous stimuli
9) is often forgetful in daily activities
(B) six or more of the following symptoms of hyperactivity-impulsivity have persisted for at
least 6 months to a degree that is maladaptive and inconsistent with developmental level:
Hyperactivity:
1) often fidgets with hands or feet or squirms in seat
2) often leaves seat in classroom or in other situations in which remaining in seat is
expected
3) often runs about or climbs excessively in situations in which it is inappropriate (in
adolescents or adults, it may be limited to subjective feelings of restlessness)
4) often has difficulty playing or engaging in leisure activities quietly
5) is often “on the go” or often acts as if “driven by a motor”
6) often talks excessively
Impulsivity
7) often blurts out answers before questions have been completed
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Table 1 (Continued)
8) often has difficulty awaiting turn
9) often interrupts or intrudes on others (e.g., butts into conversations or games)
2. Some hyperactive-impulsive or inattentive symptoms that caused impairment were present
before age 7 years.
3. Some impairment from the symptoms is present in two or more settings (e.g., at school [or
work] and at home).
4. There must be clear evidence of clinically significant impairment in social, academic, or
occupational functioning.
5. The symptoms do not occur exclusively during the course of Pervasive Developmental
Disorder, Schizophrenia, or other Psychotic Disorder and are not better accounted for by
another mental disorder (e.g., Mood disorder, Anxiety Disorder, Dissociative Disorder, or a
Personality
Disorder).
Based on these criteria, three specific subtypes of ADHD are identified:
1. ADHD, Combined Type: if both criteria 1A and 1B are met for the past 6 months
2. ADHD, Predominately Inattentive Type: if criterion 1A is met but criterion 1B is not met
for
the past six months
3. ADHD, Predominately Hyperactive-Impulsive Type: if Criterion 1B is met but Criterion 1A
is not met for the past six months

ADHD Epidemiology
Approximately 7 to 15% of school-aged children in the US have a diagnosis of ADHD
(Lingineni et al., 2012; Minzenberg, 2012; Visser, Danielson, Bitsko, Perou, & Blumberg, 2013).
ADHD has been reported to affect 8-12% of children globally (Minzenberg, 2012; Visser et al.,
16

2013). Symptoms of ADHD frequently persist into adulthood in as many as 65% of cases
(Faraone, Biederman, & Mick, 2006). One study reported a 5% prevalence of ADHD among US
adults (Kessler et al., 2006).
ADHD is a heritable disorder, with several reports stating up to 60-70% of offspring are
affected (Franke, Neale, & Faraone, 2009; Lesch et al., 2008). A study by Goodman and
Stevenson reported concordance of hyperactivity symptoms in 51% of monozygotic twins
compared with 33% of dizygotic twins (Goodman & Stevenson, 1989). The main two genetic
polymorphisms identified to be genetic risk factors for ADHD reside in the dopamine receptor
and dopamine transporter genes (Smith, Mick, & Faraone, 2009; Swanson et al., 2001).
Environmental factors shown to be associated with ADHD include lead exposure,
maternal use of alcohol and/or tobacco (Brion et al., 2010; Lindblad & Hjern, 2010), and low
birth weight and premature delivery (Froehlich et al., 2011; Mick, Biederman, Faraone, Sayer, &
Kleinman, 2002), all of which may be associated with one another. Children and adults affected
by ADHD are more likely to be male, non-Hispanic white, and have lower income and education
levels (Bernardi et al., 2012; Lingineni et al., 2012). ADHD is independently associated with
other psychiatric disorders such as depression, anxiety, conduct, and personality disorders
(Rowland et al., 2002; Yoshimasu et al., 2012). A study by Bernardi et al assessed the lifetime
impact of ADHD using data from the National Epidemiologic Survey on Alcohol and Related
Conditions (Bernardi et al., 2012). Bernardi and colleagues found ADHD to be associated with
prevalence of another psychiatric disorder, any alcohol use disorder, problems with money and
gambling, reckless driving, quitting a job without a plan, sudden changes in personal career
plans, and frequent number of lifetime traumas (Bernardi et al., 2012).
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ADHD Treatment
Treatment for ADHD includes medication that alters one or both of the major
catecholamine neurotransmitters systems in the brain and/or cognitive behavioral therapy
(Minzenberg, 2012). In the National Comorbidity Study Adolescent Supplement, approximately
60% of adolescents’ age 13 to 18 years with an ADHD diagnosis had sought treatment for
ADHD at the time of the survey (Merikangas et al., 2011). A smaller proportion of adults, only
25% with ADHD diagnosis, reported seeking treatment for ADHD in the National Comorbidity
Survey Replication (Kessler et al., 2006). Results from the National Survey of Children’s
Health reported 66% of children ages 2-17 years were currently taking medication for ADHD,
the proportion ranged from 33% in Nevada to 79% in Mississippi. The proportion of children on
medication was higher among boys than girls across the age span (Visser et al., 2013). A recent
systematic review of randomized control trials assessing the effect of ADHD treatment found
that at 14 months treatment with stimulant medication alone or combined with psychotherapy
was still effective in minimizing ADHD symptoms (Parker, Wales, Chalhoub, & Harpin, 2013).

T1D and ADHD
In order to adequately manage their diabetes, individuals with T1D must make frequent
decisions every day regarding their diabetes. For good glycemic control, it is necessary to
frequently monitor blood glucose levels and decide based on those glucose numbers, what to eat,
how much insulin to take, and when or if to exercise. All of these decisions are rooted in
executive functioning and require organization, working memory, self-regulation, and careful
planning and problem solving. It is easy to see how someone with T1D and ADHD could
struggle with the day to day requirements of managing diabetes, particularly adolescents and
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young adults who already are vulnerable to nonadherence. The adolescent period creates
multiple challenges to diabetes management, including the psychological struggle for
independence from parents with greater reliance on peer relationships and physiological changes
causing insulin resistance, leading to increased insulin requirements and fluctuations in glucose
levels. Data from the T1D Exchange registry show that adolescents and young adults have the
highest HbA1c with a mean HbA1c of 9.0% among those age 13-<18 and 8.4% among those 18<26 ( Miller, 2015).
Poor adherence to diabetes management is one of the primary reasons for referral of
youth with T1D to psychological services (Sanchez 2006). One study evaluating the process of
psychological consultation with an outpatient diabetes service found that among the 50 children
referred for poor glycemic control, 31% met the criteria for an ADHD diagnosis, 23% for a
mood disorder diagnosis, and 7% for an anxiety disorder diagnosis (Gelfand et al., 2004).
Whether ADHD is
associated with poor diabetes management behaviors, worsening glycemic control, and increased
frequency of acute adverse events including DKA and severe hypoglycemia has not been well
studied. No studies specifically assessing the association between ADHD and glycemic control
were found in a review of the literature. Case studies of 2 adolescents with T1D and ADHD by
Sanchez, Chronis, and Hunter demonstrated an improvement in adherence to diabetes
management behaviors following evidence based treatment for ADHD (Sanchez, Chronis,
Hunter 2006). An abstract assessing the association between ADHD and diabetes management
among adolescents with T1D was presented as a poster at the 72nd American Diabetes
Association Scientific Sessions. Duke and colleagues examined data from 64 adolescents (28%
with ADHD diagnosis) with poorly controlled diabetes who were participating in a larger study.
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The 18 study participants with ADHD were more likely to score lower on the Diabetes SelfManagement Profile (DSMP) compared with participants without ADHD (Duke, 2012).
A recent 2010 study by McNally and colleagues investigating the relationship between
executive functioning (not specifically ADHD), diabetes adherence and glycemic control in 235
children with T1D found that high levels of executive functioning were associated with better
adherence, better adherence was associated with improved glycemic control, and the relationship
between executive functioning and glycemic control was modified by treatment adherence
(McNally, Rohan, Pendley, Delamater, & Drotar, 2010).
The primary objective of this study is to determine whether ADHD influences glycemic
control among adolescents and young adults with T1D. Secondary objectives include assessing
the impact of ADHD on diabetes management and acute events including DKA and severe
hypoglycemia. It is important to assess the impact of ADHD on glycemic control due to the
strong causal relationship between HbA1c (a common measure of glycemic control) and the risk
of long-term complications of T1D (The Diabetes Control and Complications Trial Research
Group, 1993). Acquisition of such knowledge will allow for the development and testing of
behavioral interventions and optimal therapeutic regimens for the studied population.
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CHAPTER 3:
METHODS
This study was conducted utilizing data from the T1D Exchange Clinic Registry, the first
initiative of the T1D Exchange Clinic Network. The T1D Exchange Clinic Network is
coordinated by the Jaeb Center for Health Research, a nonprofit clinical research coordinating
center in Tampa, Florida. There are 72 pediatric and adult clinical centers that make up the
Clinic Network. The centers were selected to provide a broad representation of pediatric and
adult patients with T1D covering 32 states including some states that typically have not had
centers in multicenter studies of diabetes such as North Dakota, South Dakota, Montana and
Idaho (Figure 1). Fifty-six centers are institution-based, 15 are community-based, and 1 is a
managed care type center. Of the 72 centers, 37 care for pediatric patients, 22 care for adult
patients, and 13 are a mix of both pediatric and adult.

Figure 1. T1D Exchange Clinic Network Clinical Centers
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T1D Exchange Clinic Registry Enrollment
To be enrolled in the T1D Exchange Clinic Registry, an individual must have had a
clinical diagnosis of presumed autoimmune T1D and either islet cell antibodies present or if
antibodies were negative or unknown, then insulin must have been started at or shortly after
diagnosis and used continually thereafter (except in the case of a pancreas or islet cell
transplant).
Written informed consent was obtained from adult participants and parents/guardians of
minor participants, who were required to understand either English or Spanish to participate.
Minor participants provide written assent, according to IRB requirements. Data were collected
for the registry database at enrollment and are currently being collected annually. Sites are
compensated for each enrolled participant and participants receive either a gift card or alternately
can select a donation for a T1D charity each time they are asked to complete a questionnaire.

Data Collection at Registry Enrollment
For the 25,833 participants enrolled from August 2010 through July 2012 the enrollment
data collection consisted of 2 components: (1) completion of a questionnaire by the participant or
parent of participant (parent completed questionnaire if participant’s age was < 13 and either the
participant or the parent choose to complete questionnaire if participant’s age was 13-17) and (2)
retrieval of information extracted from the medical record.

At enrollment the majority (51%) of

participants completed the questionnaire electronically in the clinic on project-supplied iPads or
laptop computers, 29% in the clinic on paper, and 20% from home, either on paper or
electronically (Beck et al., 2012).
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The participant questionnaire was comprised of a series of modules that address diabetes
history, management, monitoring and complications; general health; lifestyle; family history;
socioeconomic factors; and menstrual and pregnancy history. Both English and Spanish versions
of the questionnaire were provided. The clinic chart data extraction captures information on the
diagnosis of T1D, acute events such assevere hypoglycemia and DKA, medications, medical
conditions and diabetes-related complications, and laboratory results.

Data Collection at Annual Visits
The year 1 data collection consisted of both a participant questionnaire and clinic medical
record extraction for the first 17,474 participants. Currently, annual updates for enrolled registry
participants consist of medical record extraction only.
The web application for the year 1 questionnaire was developed such that the
questionnaire completed by each participant was customized to address specific objectives in
subsets of participants such as participants using an insulin pump or who report having ADHD.
An initial questions module determined which modules a participant would receive based on
their answers to key questions (Miller, 2013).

Study Methods
This study includes 7,380 registry participants who were 13 -<26 years of age at the time
of completion of the year 1 questionnaire with T1D duration of at least 1 year and not pregnant at
the time of the year 1 data collection. Among the 7,380 participants, 774 self-reported a
diagnosis of ADHD. Participants who did not report a diagnosis of ADHD but who had a record
of a diagnosis or medication in the clinic chart were excluded to avoid misclassification.
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Exposure Assessment
The diagnosis of ADHD was obtained through participant report from the 1-year
questionnaire with the following question: Have you ever been told by a doctor (physician,
psychiatrist, or psychologist) that you have Attention Deficit Hyperactivity Disorder (ADHD) or
Attention Deficit Disorder (ADD)? Medications and treatment for ADHD were collected through
an ADHD module on the year 1 participant questionnaire (Appendix A).
Participants were classified into 3 groups for the primary analyses using participant
reported diagnosis and medication use: ADHD w/o meds, ADHD with meds, and No ADHD.
Secondary analyses classifying participants into the following groups was conducted: 1) No
ADHD; 2) ADHD with medication and psychosocial therapy; 3) ADHD with medication only;
4) ADHD with psychosocial therapy only; 5) ADHD with no treatment. The proportion of
participants who have a clinical diagnosis of ADHD and/or medication recorded in the
endocrinologist medical chart also was assessed. Sensitivity analysis only including participants
with concordant ADHD diagnosis between participant and clinic report was performed.

General Statistical Methods
Pre-planned stratified analyses for age groups of 13-<18 and 18-<26 was conducted since
it was expected that these groups may differ in the way diabetes is managed and in access to
ADHD medication and treatment. The association between participant demographic and clinical
characteristics and ADHD status was assessed using chi-square or t-tests. For all specific aims
described below regression diagnostics were performed and the assumption of normality for
linear models was assessed through plotting the distribution of residuals. A rank transformation
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was used to obtain test of significance if the normality assumption was violated. Participants
missing the outcome of interest were excluded from the analysis. For ordinal and continuous
co-variates missing values were imputed and an indicator for missing was included in the model
to adjust for the imputation. Missing was included as a separate category for categorical covariates. Analysis was performed using SAS version 9.4. Tests of significance were 2-sided
and p values < 0.05 were considered statistically significant.

Methods for Specific Aim #1: Compare Glycemic Control among Adolescents and Young
Adults with T1D across ADHD Status Groups.
The study design for specific aim #1 is cross sectional. The most recent available
HbA1c level within 6 months prior to the year 1 data collection was compared between ADHD
classification groups using a linear mixed model adjusting for random site effects and potential
confounders including age group (when not stratified), T1D duration group (based on reviewing
distribution of data), gender, race/ethnicity, annual household income (ordinal), insurance status,
and clinical diagnosis of depression.

Methods for Specific Aim #2: Assess the Relationship between ADHD Status and Diabetes
Management Including Glucose Monitoring and Insulin Administration in Adolescents and
Young Adults with T1D.
The study design for specific aim #2 is cross sectional. Participants were classified as
insulin pump or injection users from the clinic medical record. A participant was classified as
using continuous glucose monitoring (CGM) if both the clinic and participant reported using
CGM in the past 30 days. Information on frequency of blood glucose checks per day and missed
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insulin doses were obtained from the participant/parent questionnaire with the following
questions:
•

About how many times per day are you (is your child) checking your (his/her) blood
sugar with a blood glucose meter?

•

In a typical week, how often do you miss an insulin dose? Never; Less than once a week;
1 to 2 times a week; 3 to 4 times a week; 5 or more times a week; At least once a day.
Linear mixed models were performed to compare the number of SMBG measurements

per day between ADHD classification groups adjusting for random site effects and other
potential confounding factors including age group, T1D duration group (based on reviewing
distribution of data), gender, race/ethnicity, annual household income (ordinal), and insurance
status. Outliers with SMBG > 13 were truncated at 13 for tabulating the mean and in regression
models.
Frequency of missing an insulin dose was categorized into a binary variable by collapsing
never and less that once a week vs. at least once per week. Differences in binary outcomes
between ADHD classification groups were assessed through logistic regression models adjusting
for a random site effects and for potential confounders including age group (when not stratified),
diabetes duration (based on data distribution), gender, race/ethnicity, annual household income
(ordinal), and insurance status.
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Methods for Specific Aim #3: Assess the Association between ADHD Status and the
Frequency of Diabetic Ketoacidosis (DKA) and Severe Hypoglycemia among Adolescents and
Young Adults with T1D.
Frequency of diabetic ketoacidosis (DKA) and severe hypoglycemia in the 3 months
prior to the registry 1 year data collection were obtained from the participant questionnaire. The
occurrence of participant reported DKA and severe hypoglycemia was obtained in the following
way:
In the past 3 months, about how many times have you experienced any of the following events:
1. Severe low blood sugar (hypoglycemia) that resulted in passing out, losing consciousness,
or seizure:
◻ 0 ◻ 1

◻2

◻3 ◻ 4

◻ 5

◻6

◻7

◻ 8

◻ 9

◻ More than 9

2. Diabetic ketoacidosis (high blood sugar plus ketones, also known as DKA) diagnosed by
a doctor for which you went to either the hospital, emergency room, or another
healthcare facility?
◻ 0 ◻ 1

◻2

◻3 ◻ 4

◻ 5

◻6

◻7

◻ 8

◻ 9

◻ More than 9

Frequency of at least 1 DKA and SH event in the past 3 months was used for analysis
instead of the number of events due to concerns with the accuracy of the exact number of
participant reported events.

Logistic regression models were performed to compare the frequency of DKA and severe
hypoglycemia between ADHD classification groups. Multivariate models were adjusted for
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random site effects and other potential confounders including age group (when not stratified),
diabetes duration group (based on distribution of data), gender, race/ethnicity, annual household
income, and diagnosis of depression.
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CHAPTER 4:
RESULTS
Analysis included 7,380 participants age 13 to 25 years with duration of T1D of at least
one year who met the eligibility criteria listed above; 183 participants who did not report a
diagnosis of ADHD but who had a record of a diagnosis or medication for ADHD entered from
the clinic chart were excluded. Participant characteristics overall and by age group are shown in
Table 2.

Table 2. Participant Characteristics
Overall

Age Group
13-<18 years old 18-<26 years old

N=7380

N=4688

N=2692

Age - mean±SD

17.4±3.1

15.4±1.4

20.8±2.1

Gender - Female

3663 (50%)

2308 (49%)

1355 (50%)

White Non-Hispanic

5948 (81%)

3712 (79%)

2236 (83%)

Black Non-Hispanic

361 (5%)

256 (5%)

105 (4%)

Hispanic or Latino

732 (10%)

494 (11%)

238 (9%)

Other

339 (5%)

226 (5%)

113 (4%)

Race/Ethnicity
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Table 2 (Continued)
Overall

Age Group
13-<18 years old

18-<26 years old

N=7380

N=4688

N=2692

< $35,000

109 (15%)

625 (13%)

468 (17%)

$35,000 - < $75,000

136 (19%)

890 (19%)

477 (18%)

≥ $75,000

2683 (36%)

1869 (40%)

814 (30%)

Missing

2237 (30%)

1304 (28%)

933 (35%)

Private Insurance

5007 (68%)

3206 (68%)

1801 (67%)

Other Insurance

1499 (20%)

1048 (22%)

451 (17%)

76 (1%)

32 (<1%)

44 (2%)

798 (11%)

402 (9%)

396 (15%)

79 (1%)

44 (<1%)

35 (1%)

Normal weight

4144 (56%)

2852 (61%)

1292 (48%)

Overweight

1838 (25%)

1110 (24%)

728 (27%)

Obese

992 (13%)

636 (14%)

356 (13%)

Missing

327 (4%)

46 (<1%)

281 (10%)

7.7±4.7

6.4±3.9

9.9±5.1

Annual Household Income

Insurance Status

No insurance
Missing
BMI Category
Underweight

Diabetes Duration (years)Mean±SD
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Table 2. (Continued)
Overall

Age Group

N=7380

13-<18 years old

18-<26 years old

N=4688

N=2692

Diabetes Duration Group
1-<10 years

4909 (67%)

3574 (76%)

1335 (50%)

10-<20 years

2383 (32%)

1114 (24%)

1269 (47%)

20-<50 years

88 (1%)

0 (0%)

88 (3%)

Insulin Pump Use

4123 (56%)

2640 (56%)

1483 (55%)

361 (5%)

190 (4%)

171 (6%)

CGM Use

A diagnosis of ADHD was self-reported by 774 (10.4%) of the 7,380 participants. A
diagnosis of ADHD was more common among participants who were male, were of white nonHispanic race, had lower SES and had a diagnosis of depression in the medical chart (Table 3).

Table 3. ADHD Diagnosis According to Participant Characteristics
ADHD Diagnosis
Overall
7380

All

# with Diagnosis
P value
N (%)
774 (10%)
0.36

Age Group
13-<18 years old

4688

480 (10%)

18-<26 years old

2692

294 (11%)
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Table 3 (Continued)
ADHD Diagnosis
Overall

# with Diagnosis
P value
N (%)
<0.001

Gender
Female

3663

269 (7%)

Male

3717

505 (14%)
0.003

Race/Ethnicity
White Non-Hispanic

5948

654 (11%)

Black Non-Hispanic

361

28 (8%)

Hispanic or Latino

732

52 (7%)

Other Race/Ethnicity

339

40 (12%)
0.65

T1D Duration
1-2 years

1104

127 (12%)

3-5 years

1701

175 (10%)

6-9 years

2104

212 (10%)

≥ 10 years

2471

260 (11%)
0.005

Annual Household Income
< $35,000

1093

148 (14%)

$35,000 - < $75,000

1367

135 (10%)

≥$75,000

2683

266 (10%)

Missing

2237

225 (10%)

32

Table 3 (Continued)
ADHD Diagnosis
Overall

# with Diagnosis
P value
N (%)
0.001

Insurance Category
Private Insurance

5007

506 (10%)

Other Insurance

1499

196 (13%)

No insurance

76

7 (9%)

Missing

798

65 (8%)
0.64

BMI Category
Underweight

79

8 (10%)

Normal weight

4144

432 (10%)

Overweight

1838

176 (10%)

Obese

992

114 (11%)

Missing

327

44 (13%)

Diagnosis of Depression

<0.001

No

6844

642 (9%)

Yes

536

132 (25%)

*Chi-square test was used to obtain p value

The mean±SD age of diagnosis of ADHD was 10.0±4.6 years. A diagnosis of ADHD
was made prior to the diagnosis of T1D in 42% of participants, at the same age in 8% of
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participants, and after the diagnosis of T1D in 50% of participants. Figure 2 (see page 34) shows
the breakdown of ADHD treatment status among the 774 participants with ADHD.

No treatment

Counseling only

Meds only

Meds and counseling

100%
75%
50%

45%

40%

7%

8%

19%

21%

29%

31%

52%

6%
17%

25%
25%

0%
Overall
N=774

13-17 yrs
N=480

18-25 yrs
N=2692

Figure 2. ADHD Treatment Status

A crosstab of self-reported ADHD diagnosis and medication use and clinic reported diagnosis
and medication use is shown in Table 4 (see page 35).

Participants who reported no ADHD diagnosis or who responded ‘do not wish to answer’
but had a diagnosis of ADHD in the medical chart or an ADHD medication were excluded
(N=183).
Among the 7,380 participants, 403 (5%) had a self-reported diagnosis of ADHD and
were not currently taking medication (Group A: ADHD w/o meds), 371(5%) had a diagnosis of
ADHD and were currently taking medication (Group B: ADHD with meds), and 6,606 (90%) did
not have a diagnosis of ADHD (Group C: No ADHD).
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Table 4. Crosstab of ADHD Self-Reported Status and Clinic Reported Status
Self-Reported
ADHD Status
Frequency
Percent
Row Pct
Col Pct
ADHD not on meds

ADHD on meds

No ADHD

Do not wish to answer

Total

Clinic ADHD Status

ADHD
ADHD
without meds with meds

No
ADHD

Med for
ADHD but no
Total
diagnosis in
chart

80

43

255

25

403

1.06

0.57

3.37

0.33

5.33

19.85

10.67

63.28

6.20

53.69

17.41

3.65

14.37

37

167

61

106

371

0.49

2.21

0.81

1.40

4.91

9.97

45.01

16.44

28.57

24.83

67.61

0.87

60.92

29

31

6606

41

6707

0.38

0.41

87.35

0.54

88.68

0.43

0.46

98.49

0.61

19.46

12.55

94.47

23.56

3

6

71

2

82

0.04

0.08

0.94

0.03

1.08

3.66

7.32

86.59

2.44

2.01

2.43

1.02

1.15

149

247

6993

174

7563

1.97

3.27

92.46

2.30

100.00

ADHD status groups differed with respect to age, race/ethnicity and SES with the ADHD
with meds group having a higher percentage of adolescents, white non-hispanic, and higher SES
participants compared with the ADHD w/o meds group (Table 5, see page 36).
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Table 5. Participant Characteristics According to ADHD Status Groups
ADHD Status
Group A:
ADHD w/o
meds
N=403

Group B:
ADHD with
meds
N=371

Group C:
No ADHD
N=6,606

N (%)

N (%)

N (%)

P Value
0.02

Age Group – N(%)
13-<18 years old

232 (58%)

248 (67%)

4208 (64%)

18-<26 years old

171 (42%)

123 (33%)

2398 (36%)
<0.001

Gender
Female

138 (34%)

131 (35%)

3394 (51%)

Male

265 (66%)

240 (65%)

3212 (49%)
<0.001

Race/Ethnicity
White Non-Hispanic

322 (80%)

332 (89%)

5294 (80%)

Black Non-Hispanic

19 (5%)

9 (2%)

333 (5%)

Hispanic or Latino

33 (8%)

19 (5%)

680 (10%)

Other Race/Ethnicity

29 (7%)

11 (3%)

299 (5%)
0.88

T1D Duration Group
1-2 years

62 (15%)

65 (18%)

977 (15%)

3-5 years

93 (23%)

82 (22%)

1526 (23%)

6-9 years

113 (28%)

99 (27%)

1892 (29%)

≥ 10 years

135 (33%)

125 (34%)

2211 (33%)
<0.001

Annual Household Income
< $35,000

89 (22%)

59 (16%)

945 (14%)

$35,000 - < $75,000

75 (19%)

60 (16%)

1232 (19%)

≥ $75,000

114 (28%)

152 (41%)

2417 (37%)

Missing

125 (31%)

100 (27%)

2012 (30%)
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Table 5 (Continued)
ADHD Status
Group A:
ADHD w/o
meds
N=403
N (%)

Group B:
ADHD with
meds
N=371
N (%)

Group C:
No ADHD
N=6,606
N (%)

P Value
<0.001

Insurance Category
Private Insurance

246 (61%)

260 (70%)

4501 (68%)

Other Insurance

119 (30%)

77 (21%)

1303 (20%)

No insurance

7 (2%)

0-

69 (1%)

Missing

31 (8%)

34 (9%)

733 (11%)
0.89

BMI Category
Underweight

3 (<1%)

5 (1%)

71 (1%)

Normal

216 (54%)

216 (58%)

3712 (56%)

Overweight

90 (22%)

86 (23%)

1662 (25%)

Obese

70 (17%)

44 (12%)

878 (13%)

Missing

24 (6%)

20 (5%)

283 (4%)
<0.001

Depression Diagnosis
No

342 (85%)

300 (81%)

6202 (94%)

Yes

61 (15%)

71 (19%)

404 (6%)

Specific Aim 1: Glycemic Control
Mean HbA1c was significantly higher in the ADHD w/o meds (mean 9.0%±1.8%,
p<0.001) and ADHD with meds (8.9%±1.7%, p=0.002) compared with the No ADHD group
(8.6%±1.7) (Figure 3, see page 38).
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Figure 3. Boxplot of HbA1c by ADHD Status

This relationship remained consistent after adjustment for confounders including age group,
gender, race/ethnicity, annual household income, insurance status and clinical diagnosis of
depression and within both age group strata (Table 6, see page 39).
Significant differences between the No ADHD and ADHD w/o meds (P=0.002) and
ADHD with meds (P=0.001) remained when adjustment for insulin pump use (potentially on the
causal pathway) was added to the adjusted model and when depression was removed as a
covariate in the adjusted model (P<0.001 for both ADHD groups vs. no ADHD). A similar
relationship was observed when analysis was limited to those with clinic confirmed ADHD
diagnosis (Table 7, see page 40).
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Table 6. Glycemic Control and ADHD Status

HbA1c*

Unadjusted Estimate (95% CI)
for difference

Unadjusted

Adjusted Estimate (95%
CI) for differenceᵅ

Adjusted

P-value

P-valueᵅ

N

Mean±Std

A. ADHD w/o meds

389

9.0%±1.8%

0.4% (0.2%, 0.6%)

<0.001

0.3% (0.1%, 0.5%)

<0.001

B. ADHD with meds

365

8.9%±1.7%

0.3% (0.1%, 0.5%)

<0.001

0.3% (0.1%, 0.5%)

0.002

C. No ADHD

6511

8.6%±1.7%

A. ADHD w/o meds

225

9.1%±1.9%

0.4% (0.2%, 0.6%)

<0.001

0.2% (0.01%, 0.4%)

0.04

B. ADHD with meds

244

9.0%±1.6%

0.3% (0.1%, 0.5%)

0.02

0.2% (0.02%, 0.4%)

0.03

C. No ADHD

4172

8.7%±1.7%

A. ADHD w/o meds

164

8.8%±1.7%

0.4% (0.1%, 0.7%)

0.003

0.4% (0.1%, 0.6%)

0.01

B. ADHD with meds

121

8.7%±1.9%

0.4% (0.1%, 0.7%)

0.03

0.4% (0.1%, 0.7%)

0.01

C. No ADHD

2339

8.4%±1.8%

Overall

Age Group: 13-<18 years

Age Group: 18-<26 years

*HbA1c is missing for 14 (3%) participants in the ADHD w/o meds group, 6 (2%) participants in the ADHD with meds group and 95
(2%) in the no ADHD group
ᵅAdjusted for age group (when not stratified), T1D duration, gender, race/ethnicity, annual household income, insurance status and
depression diagnosis
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Table 7. Glycemic Control and Clinic Confirmed ADHD Status

HbA1c

Adjusted Estimate (95%
CI) for difference

P-value

N

Mean±Std

Clinic confirmed ADHD w/o
meds

119

9.1%±1.7%

0.4% (0.1%, 0.7%)

0.007

Clinic confirmed ADHD with
meds

199

8.9%±1.7%

0.3% (0.1%, 0.5%)

0.02

Clinic confirmed
NO ADHD

6513

8.6%±1.7%

*Adjusted for age group (when not stratified), T1D duration, gender, race/ethnicity, annual
household income, insurance status and depression diagnosis

When further classifying ADHD status by whether or not the participant was receiving
psychological counseling significantly higher HbA1c levels were observed for all ADHD groups
compared with No ADHD except for the group who reported taking medication and receiving
psychological therapy (Table 8).

Table 8. Glycemic Control and ADHD Combined Treatment Status

HbA1c

Adjusted Estimate
(95% CI) for
difference*

P-value*

N

Mean±Std

On meds and seeing psych

215

8.8%±1.7%

0.2% (-0.0%, 0.4%)

0.10

On meds and NOT seeing psych

150

8.9%±1.7%

0.4% (0.2%, 0.7%)

0.002

Not on meds but seeing psych

56

9.6%±1.9%

0.6% (0.2%, 1.0%)

0.005

Not on meds or seeing psych

334

8.9%±1.8%

0.2% (0.1%, 0.4%)

0.01

No ADHD

6513

8.6%±1.7%

*Adjusted for age group (when not stratified), T1D duration, gender, race/ethnicity, annual
household income, insurance status and depression diagnosis
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Participants with ADHD with or without meds were significantly less likely to meet the ADA
clinical target for HbA1c of < 7.5% for participants 13- 17 years and < 7.0% for participants 1825 years (Figure 4)

100%
ADHD w/o meds
80%

ADHD with meds
No ADHD

60%
A1c Goal = <7.0%

A1c Goal = <7.5%
40%
P<0.001

15%

20%

P<0.001

21%

P<0.001

15%

7%

P<0.001

17%

11%

0%
13-17 yrs

18-25 yrs

Figure 4. Proportion of Participants Meeting ADA Targets According to ADHD Status

Specific Aim 2: Assess the Relationship between ADHD Status and Diabetes Management
Including Glucose Monitoring and Insulin Administration in Adolescents and Young Adults
with T1D.
SMBG
Mean SMBG per day was 4.7, 5.1, and 4.9 in the ADHD w/o meds, ADHD with meds,
and No ADHD groups, respectively (Figure 5, page 42).
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Figure 5. SMBG by ADHD Status
No significant differences between ADHD status groups were observed in an adjusted model
overall or stratified by age group (Table 9, see page 43).
Overall, 33% of participants in the ADHD w/o meds reported performing SMBG less
than the recommended 4 times per day compared with 26% of participants in the no ADHD
group (Figure 6, see page 44).
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Table 9. SMBG per Day and ADHD Status

SMBG

Unadjusted
Estimate (95%
CI) for
difference

Unadjusted
P-value

Adjusted
Estimate
(95% CI) for
differenceᵅ

Adjusted
P-valueᵅ

N

Mean

A. ADHD w/o
meds

394

4.7±2.3

-0.2 (-0.5, 0.0)

0.05

-0.0 (-0.2, 0.2)

0.87

B. ADHD with
meds

362

5.0±2.4

0.1 (-0.1, 0.3)

0.38

0.1 (-0.1, 0.3)

0.43

C. NO ADHD

6498

4.9±2.2

228

5.1±2.4

-0.1 (-0.4, 0.2)

0.53

0.1 (-0.2, 0.3)

0.70

B. ADHD with
meds

247

5.4±2.2

0.2 (-0.1, 0.5)

0.15

0.2 (-0.0, 0.5)

0.07

C. NO ADHD

4152

5.2±2.1

166

4.1±2.1

-0.3 (-0.7, 0.1)

0.09

-0.1 (-0.5, 0.2)

0.43

B. ADHD with
meds

115

4.2±2.4

-0.2 (-0.6, 0.2)

0.36

-0.3 (-0.7, 0.1)

0.18

C. NO ADHD

2346

4.4±2.3

Overall

Age Group: 13<18 years
A. ADHD w/o
meds

Age Group: 18<26 years
A. ADHD w/o
meds

*SMBG is missing for 9 (2%) participants in the ADHD w/o meds group, 9 (2%) participants in
the ADHD with meds group and 108 (2%) in the no ADHD group
ᵅAdjusted for age group (when not stratified), site, T1D duration, gender, race/ethnicity, annual
household income, insurance status, and depression diagnosis

Continuous Glucose Monitoring
A continuous glucose monitor was being use by 5%, 7% and 5% of participants in the
ADHD w/o meds, ADHD with meds, and No ADHD groups, respectively. Significant
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differences between groups was not observed for the overall cohort but there was a trend towards
higher CGM use in the ADHD with meds group among young adults (Table 10, see page 45).

100%

ADHD w/o Meds

ADHD with Meds

No ADHD

80%
P=0.25 P=0.54
60%

P=0.002

P=0.01

P=0.58
40%

P=0.33

44%

41%

39%

33%
24%

26%

26%
16%

20%

18%

0%
N=394 N=362 N=6498
Overall

N=228 N=247 N=4152
N=166 N=115 N=2346
13-<18
18-<26
Age, years

Figure 6. SMBG <4 times per day and ADHD Status
Insulin Delivery Method
An insulin pump was being used for insulin delivery by 47%, 58% and 56% of
participants in the ADHD w/o meds, ADHD with meds, and No ADHD groups, respectively.
Overall the ADHD w/o meds participants were significantly less likely to be using an insulin
pump compared with participants who did not have ADHD (P=0.02) (Table 11, see page 46).
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Table 10. Continuous Glucose Monitoring Use by ADHD Status

CGM Use

Unadjusted
Odds Ratio
(95% CI)

Unadjusted
P-value

Adjusted Odds
Ratio (95% CI)

Adjusted
P-value*

N

#(%)

A. ADHD w/o
meds

403

21 (5%)

1.08 (0.69, 1.71)

0.73

1.16 (0.73, 1.84)

0.54

B. ADHD with
meds

371

26 (7%)

1.48 (0.97, 2.26)

0.07

1.46 (0.95, 2.24)

0.08

C. NO ADHD

6606

314 (5%)

232

10 (4%)

1.06 (0.55, 2.04)

0.87

1.20 (0.62, 2.33)

0.59

B. ADHD with
meds

248

12 (5%)

1.21 (0.66, 2.22)

0.54

1.21 (0.65, 2.24)

0.55

C. NO ADHD

4208

168 (4%)

171

11 (6%)

1.07 (0.56, 2.02)

0.84

1.14 (0.59, 2.18)

0.70

B. ADHD with
meds

123

14 (11%)

1.86 (1.03, 3.37)

0.04

1.72 (0.94, 3.15)

0.08

C. NO ADHD

2398

146 (6%)

Overall

Age Group: 13<18 years
A. ADHD w/o
meds

Age Group: 18<26 years
A. ADHD w/o
meds

*Adjusted for age group (when not stratified), site, T1D duration, gender, race/ethnicity, annual
household income, and insurance status

Missed Insulin Doses
Missing an insulin dose at least 1 time per week was reported by 36%, 39% and 30% of
participants in the ADHD w/o meds, ADHD with meds, and No ADHD groups, respectively.
Overall, participants with ADHD with or w/o meds were significantly more likely to report
missing an insulin dose (Table 12, see page 47).
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Table 11. Insulin Pump Use by ADHD Status

Pump Use

Unadjusted
Odds Ratio
(95% CI)

Unadjusted
P-value

Adjusted Odds
Ratio (95% CI)

Adjusted
P-value*

N

#(%)

A. ADHD w/o
meds

403

191 (47%)

0.65 (0.54, 0.82)

<0.001

0.77 (0.61, 0.95)

0.02

B. ADHD with
meds

371

216 (58%)

1.07 (0.86, 1.34)

0.52

1.07 (0.85, 1.35)

0.57

C. NO ADHD

6606

3716 (56%)

232

111 (48%)

0.65 (0.49, 0.86)

0.003

0.74 (0.55, 1.0)

0.05

B. ADHD with
meds

248

142 (57%)

1.03 (0.78, 1.35)

0.85

1.03 (0.77, 1.37)

0.85

C. NO ADHD

4208

2387 (57%)

171

80 (47%)

0.71 (0.51, 0.97)

0.03

0.79 (0.57, 1.1)

0.16

B. ADHD with
meds

123

74 (60%)

1.19 (0.81, 1.73)

0.38

1.12 (0.76, 1.65)

0.58

C. NO ADHD

2398

1329 (55%)

Overall

Age Group: 13<18 years
A. ADHD w/o
meds

Age Group: 18<26 years
A. ADHD w/o
meds

*Adjusted for age group (when not stratified), site, T1D duration, gender, race/ethnicity, annual
household income, insurance status

Specific Aim 3: Assess the Association between ADHD Status and the Frequency of Diabetic
Ketoacidosis (DKA) and Severe Hypoglycemia among Adolescents and Young Adults with
T1D.

Diabetic Ketoacidosis
The occurrence of ≥ 1 DKA event in the past 3 months by ADHD Status is shown in
Table 11. The odds of having at least one DKA event in the past 3 months was 1.8 and 1.5 times
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higher in the ADHD w/o meds (P<0.001) and ADHD with meds (P=0.01) group compared with
no ADHD (Table 13, see page 28).

Table 12. Missing Insulin Doses by ADHD Status
Frequency of
Missing Insulin
Doses at least 1
time per week

Unadjusted
Odds Ratio (95%
CI)

Unadjusted
P-value

Adjusted Odds
Ratio (95% CI)

Adjusted
P-value

N

#(%)

A. ADHD
w/o meds

403

146 (36%)

1.32 (1.07, 1.64)

0.01

1.31 (1.05, 1.63)

0.02

B. ADHD
with meds

371

143 (39%)

1.49 (1.20, 1.86)

<0.001

1.41 (1.13, 1.77)

0.003

C. NO
ADHD

6606

1975 (30%)

A. ADHD
w/o meds

232

81 (35%)

1.32 (1.00, 1.78)

0.05

1.32 (0.99, 1.76)

0.06

B. ADHD
with meds

248

92 (37%)

1.52 (1.16, 2.00)

0.003

1.42 (1.07, 1.87)

0.01

C. NO
ADHD

4208

1195 (28%)

171

65 (38%)

1.27 (0.92, 1.76)

0.14

1.28 (0.92, 1.79)

0.14

B. ADHD
with meds

123

51 (42%)

1.49 (1.03, 2.16)

0.04

1.38 (0.95, 2.03)

0.09

C. No
ADHD

2398

780 (33%)

Overall

Age Group:
13-<18
years

Age Group: 18<26 years
A. ADHD
w/o meds

*Adjusted for age, site, T1D duration, gender, race/ethnicity, annual household income,
insurance status, and depression diagnosis
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Table 13. DKA According to ADHD Status
≥ 1 DKA Event
in Past 3 Months

Unadjusted
Odds Ratio
(95% CI)

Unadjusted
P-value

Adjusted Odds
Ratio (95% CI)

Adjusted
P-value*

N

#(%)

403

62 (15%)

1.96 (1.47, 2.60)

<0.001

1.79 (1.33, 2.41)

<0.001

B. ADHD
with meds

371

46 (12%)

1.53 (1.11, 2.11)

0.01

1.52 (1.09, 2.13)

0.01

C. NO
ADHD

6606

563 (9%)

232

37 (16%)

1.85 (1.28, 2.67)

0.001

1.58 (1.07, 2.31)

0.02

B. ADHD
with meds

248

33 (13%)

1.51 (1.03, 2.22)

0.03

1.44 (0.97, 2.15)

0.07

C. No
ADHD

4208

387 (9%)

171

25 (15%)

2.19 (1.39, 3.44)

<0.001

2.30 (1.43, 3.71)

<0.001

B. ADHD
with meds

123

13 (11%)

1.51 (0.83, 2.76)

0.17

1.70 (0.92, 3.16)

0.09

C. No
ADHD

2398

176 (7%)

Overall
A. ADHD
w/o meds

Age Group: 13<18 years
A. ADHD
w/o meds

Age Group: 18<26 years
A. ADHD
w/o meds

*Adjusted for age group (when not stratified), site, T1D duration, gender, race/ethnicity, annual
household income, insurance status and depression diagnosis

Severe Hypoglycemia
The occurrence of ≥ 1 SH event in the past 3 months by ADHD Status is shown in Table
14 (see page 49). The ADHD w/o meds group was significantly more likely to have had a SH
event (OR 1.7 95% CI 1.2-2.3; P<0.001) compared with the no ADHD group but the occurrence
of SH in the ADHD with meds group was similar to the no ADHD.
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Table 14. Occurrence of ≥ 1 SH event in the past 3 months by ADHD Status
≥ 1 DKA Event
in Past 3 Months

Unadjusted
Odds Ratio
(95% CI)

Unadjusted
P-value

Adjusted Odds
Ratio (95% CI)

Adjusted
P-value*

N

#(%)

A. ADHD
w/o meds

403

53 (13%)

1.86 (1.37, 2.52)

<0.001

1.70 (1.24, 2.34)

<0.001

B. ADHD
with meds

371

33 (9%)

1.23 (0.85, 1.79)

0.27

1.25 (0.86, 1.84)

0.24

C. NO
ADHD

6606

492 (7%)

232

31 (13%)

1.94 (1.30, 2.89)

0.001

1.73 (1.14, 2.62)

0.008

B. ADHD
with meds

248

23 (9%)

1.35 (0.86, 2.11)

0.19

1.31 (0.82, 2.09)

0.25

C. NO
ADHD

4208

302 (7%)

171

22 (13%)

1.71 (1.06, 2.75)

0.03

1.72 (1.04, 1.05)

0.03

B. ADHD
with meds

123

10 (8%)

1.03 (0.53, 2.00)

0.93

1.17 (0.59, 2.32)

0.64

C. NO
ADHD

2398

190 (8%)

Overall

Age Group:
13-<18 years
A. ADHD
w/o meds

Age Group:
18-<26 years
A. ADHD
w/o meds

*Adjusted for age, site, T1D duration, gender, race/ethnicity, annual household income,
insurance status and depression diagnosis
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CHAPTER 5:
DISCUSSION
In this large cohort of adolescents and young adults with T1D, participants with a
diagnosis of ADHD with or without current medication had significantly worse glycemic control
compared with their no ADHD diagnosis counterparts even after adjustment for confounders
such as socioeconomic status, gender, and the presence of co-morbid depression. A similar
association was observed within adolescent (13-17) and young adult (18-25) age groups and
when analysis was limited to those with a concurrent participant and clinic reported diagnosis.
The average HbA1c among participants with a diagnosis of ADHD who were and were not
currently taking an ADHD medication was 9.0% and 8.9% which is higher than the average
HbA1c of 8.8% observed in the conventional therapy group of the DCCT over 30 years ago (The
Diabetes Control and Complications Trial Research Group, 1993).
The highest HbA1c was observed among ADHD teenagers who self-reported not
currently taking medication with an average HbA1c level of 9.1%. Only 15% of adolescents
with ADHD both not currently and 15% of those currently taking medication had an HbA1c
below the ADA clinical target of < 7.5% for youth less than 18 years of age. This was a
significantly lower percentage than that of participants without ADHD.
The majority of young adults age 18 to 25 also failed to achieve HbA1c levels below the
ADA target with only 7% and 11% of participants with ADHD not currently taking and currently
taking medication, respectively, having a most recent HbA1c that was below 7.0%. The
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proportion meeting the ADA target was slightly higher among young adults without a diagnosis
of ADHD (17%) but still less than a quarter.
The difference in glycemic control observed between ADHD status groups is likely
reflective of differences in adherence to diabetes management standards.

Although no

significant differences were observed for the average frequency of performing SMBG per day,
participants with ADHD without meds were more likely to perform SMBG fewer than the
recommended 4 times per day compared with no ADHD participants. Participants with ADHD
with or without current medication were more likely to report missing an insulin dose at least
once per week with 36% of those with ADHD not on meds and 39% with ADHD currently on
meds vs. 30% among those without a diagnosis. The relationship between missing insulin doses
and ADHD diagnosis remained even after adjustment for SES, age, gender, insulin delivery
method, and the presence of comorbid depression.
Use of an insulin pump for insulin delivery was less common among participants with
ADHD without medication. Only 47% of ADHD participants not currently taking medication
were using an insulin pump, whereas a pump was being used by 56% of those without an ADHD
diagnosis. The difference in insulin delivery method between the ADHD w/o meds and no
ADHD groups remained even after adjustment for SES, age, gender, diabetes duration, and
diagnosis of comorbid depression. The proportion of participants using an insulin pump in the
ADHD with meds group (57%) was similar to those without an ADHD diagnosis. Using an
insulin pump has been shown to be associated with lower blood glucose levels (Scrimgeour,
2007; Pickup 2008; Misso, 2010; Blackman, 2013) and may be particularly beneficial to those
with ADHD because of the automatic dosing of basal insulin and easier dosing of bolus/meal
time insulin.
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Although there were not statistically significant differences in CGM use between ADHD
status groups it is somewhat surprising that the use of CGM was highest among young adults
with ADHD who were currently taking medication. This could be due to CGM being prescribed
more often in those taking stimulant medication in order to more closely monitor the possible
effects of the medication on blood glucose fluctuations however, if this were the case, it seems a
higher frequency of CGM use would be observed among adolescents with ADHD who were
currently taking medication. Use of CGM may be particularly beneficial to type 1 patients with
ADHD because of the built in alarm features and the ability to have a parent or significant other
review continuous blood glucose levels either retrospectively or in real time.
ADHD status was associated with a higher frequency of at least one DKA and severe
hypoglycemic event involving seizure or loss of consciousness in the past 3 months. Participants
with a diagnosis of ADHD, not currently and currently taking medication, had 1.79 and 1.52
times the odds of reporting at least one DKA event after adjustment for SES, age, gender,
race/ethnicity and diabetes duration. DKA occurred in 16% of adolescent participants age 13 to
17 with a diagnosis of ADHD who were not currently taking medication compared with 9%
among those without ADHD. Severe hypoglycemia was also more common among ADHD
participants not currently taking treatment despite the overall higher HbA1c levels. Unlike the
early DCCT data showing higher frequency of severe hypoglycemia with lower HBA1c, recent
data from the T1D Exchange and DPV registries show no relationship between severe
hypoglycemia and low HbA1c levels likely in part due to advancements in insulin analogs. The
higher frequency of severe hypoglycemia observed in ADHD participants not taking medication
could be a reflection of greater swings in glucose levels arising from improper insulin dosing
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A review of the literature, found only a few small studies that assessed the relationship
between ADHD and diabetes management, and no studies assessing the effect of ADHD on
glycemic control. Duke and colleagues (2012) found a significant relationship between ADHD
and lower scores on a diabetes management index which supports the higher frequency of missed
insulin doses among ADHD participants observed in our study.
Previous studies have reported the negative effects of other psychological disorders
including depression and anxiety on T1D management and glycemic control. Depression and
anxiety are common co-morbid conditions of ADHD. Depression is particularly problematic
among teens and young adults with T1D. A diagnosis of depression was recorded in the medical
chart for 25% of participants with ADHD and 9% without ADHD in this study population.
Adolescents and young adults with ADHD and depression may be more likely to be receiving
psychosocial therapy and medication for ADHD than those with ADHD alone which could result
in the ADHD with medication group having higher HbA1c levels due to the negative effect of
depression. In this study a significant relationship between ADHD and glycemic control was
observed even after adjusting for depression.

Strengths
A strength of this study is the large sample size and ability to utilize the T1D Exchange
Clinic Network and registry to target a specific objective and collect participant-reported data on
ADHD diagnoses and treatment as well as the relatively low percent of missing data. This study
was able to address a research question that would be nearly impossible for a single center to
evaluate due to the relatively low prevalence of ADHD and T1D. The large sample size allowed
for subgroup analysis for adolescent and young adult age groups and ADHD medication status.
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Another strength of this analysis is the availability of participant-reported data for diabetes
management and DKA and SH events that are believed to be underreported in the medical record
(Cengiz, 2013).

Limitations
Although the T1D Exchange clinic registry data are collected from a large number of
individuals with T1D across the U.S., it is not population-based. Participation in the registry was
predicated on being followed by an endocrinologist and informed consent for each participant
was required. This is likely less of an issue with respect to representativeness of the adolescent
group in this study population since pediatric patients with T1D generally are cared for by an
endocrinologist. However, it is not known where most young adults with T1D receive care and it
may be that many are seen by a primary care physician as opposed to an endocrinologist. Where
college students receive diabetes care may be particularly problematic as some may return home
and see their pediatric endocrinologist while others may terminate their pediatric endocrinology
follow up without transition to an adult diabetes provider, thus failing to receive appropriate
monitoring by a diabetes specialist. Thus, the young adults in this cohort may or may not be fully
representative of young adults with T1D. This affects certain aspects of the data, particularly
when assessing prevalence of ADHD but is less likely to affect the primary objective of
assessing the association between ADHD and diabetes management and clinical outcomes.
Even though a diagnosis of presumed autoimmune T1D was required for registry
participation, it is possible that a small number of registry participants could have been
misdiagnosed as having T1D. However, a small number of misclassified T1D participants is not
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likely to have a meaningful effect on results due to the large sample size and it is not expected
that the misclassification would be differential across ADHD status groups.
It is also possible that there are undiagnosed ADHD cases in the group without ADHD or
that the participant report of an ADHD diagnosis was inaccurate. Performing sensitivity analysis
limiting to those with participant-reported and clinic-confirmed ADHD helps to reduce the
misclassification from erroneous reporting by participants but does not fix the limitation that
some cases of ADHD could be missed altogether. Misclassification of ADHD diagnosis would
bias results towards the null since there may be participants in the no ADHD group that have
ADHD. However, since ADHD has a relatively low prevalence the possible misclassification in
the no ADHD group is unlikely to be a major source of bias. Whether or not someone is
diagnosed with ADHD may be influenced by their level of glycemic control since they may be
more likely to be referred to a psychologist or social worker for poor diabetes management. This
phenomenon could have biased results away from the null, although it is only possible for this to
have impacted results in the 49% who were diagnosed with ADHD after the diagnosis of T1D.
Another limitation might be cases in the ADHD group that have resolved for the young
adults. The questionnaire asked whether a participant had ever been told by a physician or
psychologist that they have ADHD and does not specify whether symptoms are still present. It is
not uncommon for childhood ADHD to fully or partially resolve in adulthood. Some of the
young adults in the ADHD diagnosis group might therefore behave more like those without an
ADHD diagnosis resulting in a bias towards the null hypothesis of no difference.
It may be possible that self-reported outcomes (e.g., management) may be less reliable
among ADHD patients, possibly biasing results towards the null hypothesis. The lack of
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relationship observed between ADHD status and SMBG per day may be due to over-reporting of
frequency of SMBG by those with ADHD.
This study focuses on adolescents and young adults between the ages of 13 and 25 years
and therefore results cannot be generalized to younger or older age groups. For younger children
with T1D, diabetes management is largely driven by parents instead of the individual, making it
difficult to discern the effects of ADHD on T1D management and glycemic control. Very few
adults above the age of 25 reported a diagnosis of ADHD, therefore this population was excluded
do to small exposure sample size.
Finally, this study was a cross-sectional study and cannot conclude a causal association
between ADHD and glycemic outcomes.

Summary
Results of this study supported the working hypothesis that ADHD without treatment
with medication has a negative impact on aspects of diabetes management and glycemic control.
Participants with ADHD with and without medication were more likely to miss insulin doses,
less likely to use an insulin pump, more likely to have high HbA1c levels, and had a higher
frequency of DKA and SH. These results have important public health implications for
adolescents and young adults with T1D who are already at risk for poor glycemic control. There
was some beneficial effect of treatment with medication and psychosocial counseling with
slightly lower HbA1c levels among those who reported currently taking medication and
receiving psychosocial counseling in the past 6 months. Only a subset of participants who
reported a diagnosis of ADHD had a diagnosis recorded in the clinic chart. Since ADHD has a
meaningful impact on glycemic outcomes it is important for providers of adolescents and young
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adults with T1D to review history and signs of an ADHD diagnosis along with diagnosis of other
psychosocial disorders with their patients and consider recommending psychosocial services.
Given these results, further studies to assess interventions to improve glycemic control in
patients with T1D and ADHD are warranted.
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APPENDIX A :
ADHD and ADD Data Collection Module
1. How old were you when you were diagnosed by a doctor with ADHD or ADD?
_____________ years old
2. Have you ever taken medication for ADHD or ADD?
◻ Yes

◻ No

If YES, please answer question 3. If NO, skip to question 4.
3. Are you currently taking medication for ADHD or ADD?
◻ Yes

◻ No

4. Are you currently seeing (at least once every 3 months) a psychiatrist, psychologist, or
counselor for your ADHD or ADD?
◻ Yes

◻ No
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